Introduction:
A prominent pharma stock plans to transition from the NSE SME platform to the Main Board of NSE and BSE, aiming to significantly boost liquidity, visibility, and attract a broader, particularly institutional, investor base.
Share Price movement of Beta Drugs:
On December 26, 2024, Beta Drugs Ltd opened at ₹1995.00 and saw a high of ₹2088.95 after a low of ₹1975.00. It currently trades at ₹2020.00, up 3.65% from the previous close of ₹1948.85, with a market cap of ₹1942.00 crore.
Beta Drugs share price rise:
BDL (Beta Drugs Limited) has announced plans to transition from the SME platform to the Main Board of both the National Stock Exchange (NSE) and the Bombay Stock Exchange (BSE). This move aligns with the company’s long-term growth strategies, aiming to enhance liquidity and visibility.
The migration, intended to be completed by the end of the current financial year, is contingent on receiving necessary regulatory approvals and meeting compliance requirements. This strategic step is designed to attract a broader investor base, particularly in the institutional space.
BDL believes that moving to the Main Board will strengthen its industry position and open up greater opportunities for investors. The company is confident that this transition will facilitate the achievement of its business objectives more efficiently.
Also Read: India Rising: Investor’s Guide for 2025. Possibilities, Hindrances & Indian Stock Market in 2025
Recent news About Beta Drugs:
On November 27, 2024, Beta Drugs announced a Rs 117 crore investment from HealthQuad to enhance global expansion and operations. Aiming to be a top five oncology leader in India within five years, it focuses on strengthening manufacturing and R&D.
Also Read: NBFC stock jumps after company announces 1:5 stock split
Ace investor holding of Beta Drugs:
Ashish Kacholia, an ace investor, holds 5,56,000 shares of Beta Drugs Ltd., representing 5.78% of the company. Priced at Rs. 1996 per share, Kacholia’s stake amounts to a significant Rs. 111.0 Crores, indicating a substantial investment in the pharmaceutical company’s potential.
Onkar Singh also holds a notable position in Beta Drugs Ltd., with 1,00,800 shares, equating to 1.05% of the company. His investment, valued at Rs. 1996 per share, totals Rs. 20.1 Crores, showcasing his commitment to the company’s growth and success in the industry.
Stock performance of Beta Drugs for Period of 1 week, 6 months and 1 year:
Over the past week, Beta Drugs’ stock experienced a significant drop of 8.38%. However, over the last six months, it has shown remarkable growth of 61.1%. Additionally, on a yearly basis, the stock has increased by 29.9%, demonstrating strong long-term performance.
Also Read: Stocks to Consider for This New Year 2025
Shareholding pattern of Beta Drugs:
Summary | Sep-24 | Jun-24 | Mar-24 |
Promoter | 66.70% | 66.70% | 66.70% |
FII | 1.20% | 0.90% | 0.30% |
DII | 0.20% | 0.10% | 0.10% |
Public | 32.00% | 32.30% | 32.90% |
About Beta Drugs:
Beta Drugs Ltd. specializes in the manufacture and distribution of oncology drugs, focusing on innovative cancer treatments. The company is committed to delivering high-quality pharmaceutical products that improve patient outcomes and advance cancer care globally.
Disclaimer: The above article is written for educational purposes, and the companies’ data mentioned in the article may change with respect to time The securities quoted are exemplary and are not recommendatory.